Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FES | P07332 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | MARK3 | P27448 | 1/20 | 0.61 |
| ▸ | TYK2 | P29597 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553003 | 0.86 | FES (0.58) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL5557341 | 0.80 | KMT2A (0.60) | MEN1KMT2ACNR1CNR2NAMPT | |
| SCHEMBL5557494 | 0.79 | FES (0.76) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL18317601 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL18317211 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL18317214 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL18317546 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL18334816 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL18317996 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL1514550 | 0.78 | FLT4 (1.00) | FESRETMARK3TYK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| JP-2002537380-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | claimed |
| EP-1154998-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | Klinge Pharma GmbH (DE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050399-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | KLINGE PHARMA GMBH (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | claimed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | FES 3610/4885RET 3557/4885MARK3 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.